OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Living with cancer·Standard of care

Richter transformation of chronic lymphocytic leukaemia: the decisions you may face

Cancer page →Second-opinion finder →

4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

One path named

Excision biopsy of the PET-hottest node, histology with clonality studies, TP53 and MYC testing; restage CLL and check for cause such as BTK inhibitor progression.

Guideline
NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The path, in plain words
PET/CTStandard of care

PET and CT in one machine, so hot spots on the PET are pinned to exact locations on the CT.

  • Anatomy plus biology
  • Standard for lymphoma, lung, melanoma, head and neck staging
Also referenced:Richter transformationTP53-mutated (p53-abnormal)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
PET/CT
  • CT radiation added to PET dose
Questions to ask about this decision
  1. Is PET/CT the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (diagnosis), which of the standard options do you recommend and why?
    Why: Guideline options include: Excision biopsy of the PET-hottest node, histology with clonality studies, TP53 and MYC testing; restage CLL and check for cause such as BTK inhibitor progression.

Add these to your appointment list, or take the full question set for this cancer.

Advanced, first line

Diffuse large B-cell type, first treatment

5 optionsCompare side by side →

R-CHOP or R-EPOCH chemoimmunotherapy, with venetoclax added in trials; pirtobrutinib or a bispecific antibody in patients unfit for chemotherapy or within trials.

Guideline
NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The options, in plain words
RituximabApprovedMonoclonal antibody (anti-CD20, chimeric)

Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.

CyclophosphamideApprovedAlkylating agent (oxazaphosphorine prodrug)

Cyclophosphamide is an alkylating chemotherapy that damages DNA in dividing cells. It is part of CHOP for lymphoma, AC for breast cancer and VAC for childhood sarcomas, clears lymphocytes before CAR-T and prevents graft-versus-host disease after transplant; bladder bleeding, infertility and secondary leukaemia are its harms.

PrednisoneApprovedGlucocorticoid

Prednisone is the everyday steroid tablet in cancer care. It is the P in CHOP and MOPP for lymphoma, part of childhood leukaemia treatment, and taken with abiraterone in prostate cancer.

VenetoclaxApprovedSmall-molecule BCL-2 inhibitor

A pill that removes the survival shield from leukaemia cells, enabling chemotherapy-free, time-limited treatment for CLL.

PirtobrutinibApprovedSmall-molecule non-covalent (reversible) BTK inhibitor

A BTK blocker that works after the older ones stop, because it grips a different part of the enzyme. Fully approved for CLL in December 2025.

Also referenced:R-CHOP (lymphoma chemoimmunotherapy)
The evidence behind it
The main trade-offs on record
Rituximaball recorded rates →
Side effectAny gradeGrade 3+
Infusion-related reactions (first infusion) · Historic lymphoma data; lower with premedication77%-

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Venetoclaxall recorded rates →
  • Take with a meal and water. Avoid grapefruit, Seville oranges and starfruit.
  • Reduce by 50% in severe impairment.
Pirtobrutiniball recorded rates →
Side effectAny gradeGrade 3+
Fatigue29%-

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Questions to ask about this decision
  1. Between Rituximab, Cyclophosphamide, Prednisone and the other options, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. How closely do I match the people in Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome, and does that change what the results mean for me?
    Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
  4. Which side effects of Rituximab or Pirtobrutinib are most likely for me, which are reversible, and which would make us stop?
    Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
  5. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  6. Does your recommendation follow the current guideline (NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  7. For my situation (diffuse large b-cell type, first treatment), which of the standard options do you recommend and why?
    Why: Guideline options include: R-CHOP or R-EPOCH chemoimmunotherapy, with venetoclax added in trials; pirtobrutinib or a bispecific antibody in patients unfit for chemotherapy or within trials.
  8. Am I a candidate for Rituximab, Cyclophosphamide, Prednisone or related drugs, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  9. How do the results of Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Consolidation in responders

2 options

Allogeneic stem cell transplant for fit patients with a donor; autologous transplant where chemosensitive and no donor.

Guideline
NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The options, in plain words
Allogeneic stem cell transplantationStandard of care

Allogeneic stem cell transplantation replaces a patient's blood system with a donor's after conditioning chemotherapy, so donor immune cells hunt down leukaemia left behind. It remains the only cure for adverse-risk acute myeloid leukaemia, high-risk acute lymphoblastic leukaemia and Richter transformation, at the price of graft-versus-host disease.

  • Curative for otherwise incurable leukaemia
  • Graft-versus-leukaemia is an antigen-agnostic immune therapy
Autologous stem cell transplant (high-dose therapy)Standard of care

Autologous stem cell transplant collects the patient's own blood-forming stem cells, gives melphalan or another chemotherapy at a dose that would otherwise destroy the marrow, then returns the cells to rebuild it. It is standard consolidation in myeloma and for relapsed lymphoma, though CAR-T has displaced it in early-relapsing large B-cell lymphoma.

  • Permits dose intensity impossible otherwise
  • Decades of outcome data
  • Widely available
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
Allogeneic stem cell transplantation
  • Treatment-related mortality 10-20%
  • Chronic GVHD
  • Relapse remains the main cause of failure
Autologous stem cell transplant (high-dose therapy)
  • Treatment-related mortality ~1-2% (myeloma) to higher in children
  • Infertility, second malignancies, prolonged cytopenias
  • Being challenged by CAR-T and MRD-guided deferral
Questions to ask about this decision
  1. Between Allogeneic stem cell transplantation and Autologous stem cell transplant (high-dose therapy), which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (consolidation in responders), which of the standard options do you recommend and why?
    Why: Guideline options include: Allogeneic stem cell transplant for fit patients with a donor; autologous transplant where chemosensitive and no donor.

Add these to your appointment list, or take the full question set for this cancer.

Third line and beyond

Relapsed or chemotherapy-refractory

3 optionsCompare side by side →

Clinical trial: bispecific antibodies (epcoritamab, glofitamab), BTK inhibitor with checkpoint inhibitor, CD19 CAR-T, pirtobrutinib; palliative care.

Guideline
NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The options, in plain words
PirtobrutinibApprovedSmall-molecule non-covalent (reversible) BTK inhibitor

A BTK blocker that works after the older ones stop, because it grips a different part of the enzyme. Fully approved for CLL in December 2025.

AcalabrutinibApprovedSmall-molecule covalent BTK inhibitor (second generation)

Acalabrutinib is a cleaner BTK blocker with fewer heart and bleeding problems than ibrutinib. In February 2026 it became half of the first all-oral, fixed-duration CLL regimen.

CAR-T cell therapyApproved

A patient's T cells are removed, given a synthetic receptor that recognises the cancer, multiplied, and put back as a living drug.

  • Single infusion, durable remissions
  • MHC-independent recognition
The evidence behind it
The main trade-offs on record
Pirtobrutiniball recorded rates →
Side effectAny gradeGrade 3+
Fatigue29%-

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Acalabrutiniball recorded rates →
Side effectAny gradeGrade 3+
Headache · Mostly first weeks; responds to caffeine/paracetamol39%-
  • Avoid in severe impairment.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

CAR-T cell therapy
  • Manufacturing time and cost (~$400k+)
  • CRS, ICANS, cytopenias
  • Solid-tumour antigen heterogeneity, trafficking, exhaustion
Questions to ask about this decision
  1. Between Pirtobrutinib, Acalabrutinib and CAR-T cell therapy, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. How closely do I match the people in Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome and ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia, and does that change what the results mean for me?
    Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
  4. Which side effects of Pirtobrutinib or Acalabrutinib are most likely for me, which are reversible, and which would make us stop?
    Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
  5. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  6. Does your recommendation follow the current guideline (NCCN Guidelines: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  7. For my situation (relapsed or chemotherapy-refractory), which of the standard options do you recommend and why?
    Why: Guideline options include: Clinical trial: bispecific antibodies (epcoritamab, glofitamab), BTK inhibitor with checkpoint inhibitor, CD19 CAR-T, pirtobrutinib; palliative care.
  8. Am I a candidate for Pirtobrutinib, Acalabrutinib, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  9. How do the results of Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome and ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.